Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 17, 2026 · Filed Mar 19, 2026
Incyte's President, R&D sold $1.76M of Incyte shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,759,178
Shares × reported transaction price
35 days after results of Feb 10, 2026, 42 days before results of Apr 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $94.22 on Mar 17, 2026, 71% above its 52-week low and 15% below its high, after an 8% drop over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $110.57 (Jan 7, 2026), 70% of the way up, from 251 adjusted closes. 30 trading days earlier: $102.67 on Feb 2, 2026. Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Mar 30, 2026, 13 days after this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -0.5% | -2.2% | +1.7% |
| 30 days | +6.8% | +9.3% | -2.5% |
| 90 days | +8.2% | +15.1% | -6.9% |
| 180 days | +37.4% | +16.3% | +21.2% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.